Warsaw

• Study of MEN1703 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Recruiting
  2024-513098-31-00 4 2024-11-14 Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
• A study of AZD0901 alone or in combination with other anticancer drugs in patients with advanced/metastatic cancer. Recruiting
  2023-508275-37-00 9 2024-11-11 Gastric Cancer, Gastroesophageal Junction Cancer, Pancreatic Ductal Ad
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-fibrosis) Recruiting
  2023-509912-27-00 5 2024-11-07 Metabolic Dysfunction-Associated Steatotic Liver Disease(MASH) / Nonal
• Ruxolitinib rollover study Recruiting
  2023-507225-42-00 4 2024-11-05 Myelofibrosis
• Cytisine for nicotine-containing electronic cigarette and tobacco cigarette cessation: a randomized placebo-controlled trial Recruiting
  2023-504708-27-00 5 2024-11-02 electronic cigarette cessation
• Long-term safety and tolerability of cenerimod in adults with systemic lupus erythematosus (OPUS OLE) Recruiting
  2024-514354-67-00 5 2024-11-01 Systemic lupus erythematosus
• Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH (ENLIGHTEN-Cirrhosis) Recruiting
  2023-510395-31-00 5 2024-10-30 Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Compensat
• A trial to test the effect of obicetrapib/ezetimibe on coronary plaque characteristics on coronary computerized tomography angiography in pe … Recruiting
  2023-508475-36-00 5 2024-10-29 Atherosclerotic Cardiovascular Disease
• A Long-term Extension Study of Guselkumab in Pediatric Participants Recruiting
  2023-509560-16-00 5 2024-10-29 Juvenile psoriatic arthritis (jPsA)
• Randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of dimethyl fumarate in brain atrophy reduction, synaptic … Recruiting
  2024-517214-16-00 4 2024-10-28 Alzheimer’s disease
• MAGIC AML - Multiarm, Multicenter, RAndomized, Molecularly-GuIded Controlled Trial of Personalized Treatment Strategy - of Acute Myeloid Leu … Recruiting
  2023-503394-37-00 5 2024-10-23 Acute Myeloid Leucaemia
• A study to learn more about how well sevabertinib works and how safe it is compared with standard treatment, in participants who have advanc … Recruiting
  2024-511319-91-00 5 2024-10-23 Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
• Study of the efficacy and safety of etanercept treatment in patients with SAPHO syndrome Recruiting
  2024-516919-25-00 10 2024-10-22 SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, osteitis) i
• A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CO … Recruiting
  2023-508760-29-00 5 2024-10-21 Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
• A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting
  2023-509706-30-00 5 2024-10-18 Heart failure (HF)
• Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting
  2023-504724-25-00 5 2024-10-16 Primary Myelofibrosis
• A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Recruiting
  2023-508539-30-00 4 2024-10-10 Refractory Focal Onset Epilepsy
• IDE196 (Darovasertib) in Combination with Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Recruiting
  2023-506686-66-01 10 2024-10-09 HLA-A2 negative metastatic uveal melanoma
• An extension study to find out if multiple treatment cycles of rozanolixizumab are safe and work in children with myasthenia gravis Recruiting
  2022-502075-34-00 5 2024-10-08 Generalized Myasthenia Gravis
• 202301CPC Redefine-HF Recruiting
  2023-508581-15-00 5 2024-10-08 Heart condition
• A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis Recruiting
  2023-508817-18-00 5 2024-10-08 Perennial Allergic Rhinitis (PAR)
• This is a multicenter, double-blind, randomized study to compare the safety, effectiveness and immunogenicity (level and body resistance to … Recruiting
  2023-509775-16-00 4 2024-10-03 Ulcerative colitis
• Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting
  2023-508012-35-00 5 2024-10-02 Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB
• A Trial of Lu AG13909 in Adult Participants with Cushing’s Disease Recruiting
  2023-504733-53-00 4 2024-09-26 Cushing's Disease

Showing 601–624 of 1,708 trials